Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 11/20 | 0.43 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1242602 | 0.92 | KCNA5 (0.43) | KCNA5KCND3CYP19A1SLC6A4MEN1 | |
| SCHEMBL1243327 | 0.88 | KCNA5 (0.44) | KCNA5KCND3CYP19A1SLC6A4MAPT | |
| SCHEMBL1242824 | 0.82 | POLB (0.42) | KCNA5KCND3CYP19A1LMNAKCNH2 | |
| SCHEMBL1242782 | 0.79 | KCNA5 (0.45) | KCNA5KCND3CYP19A1SLC6A4ALDH1A1 | |
| SCHEMBL1242131 | 0.73 | CYP3A4 (0.43) | KCNA5KCND3CYP19A1SLC6A4MAPT | |
| SCHEMBL1243417 | 0.69 | POLB (0.44) | KCNA5KCND3CYP19A1SLC6A4KCNH2 | |
| SCHEMBL1240067 | 0.68 | CYP19A1 (0.53) | KCNA5CYP19A1KCNH2 | |
| SCHEMBL1242397 | 0.68 | KCNA5 (0.42) | KCNA5SLC6A4ALDH1A1LMNAKMT2A | |
| SCHEMBL1243089 | 0.68 | SYK (0.35) | KCNA5SLC6A4MAPTLMNASLC6A2 | |
| SCHEMBL1242412 | 0.66 | SLC6A2 (0.40) | KCNA5KCND3SLC6A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781635-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | KCNA5 11/4885KCND3 37/4885CYP19A1 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.